Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe
Matthew P. Goetz, MD
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
Related Items
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Web Exclusives published on April 5, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness
Web Exclusives published on April 1, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
5 mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer
Phoebe Starr
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Breast Cancer
Weight-Loss Intervention in Women with Breast Cancer Works Only with Adherence
Phoebe Starr
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Breast Cancer
Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer
Phoebe Starr
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer, Immunotherapy
Alpelisib First Drug to Improve Outcomes in Advanced Breast Cancer with PIK3CA Mutation
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer
Omega-3 Fatty Acids Significantly Reduced Pain in Obese Patients with Breast Cancer
Meg Barbor, MPH
TON - November 2018, Vol 11, No 5 published on November 28, 2018 in Breast Cancer
Working Together to Find the New Standard of Care
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
Opportunities Are Abundant for Navigators in the Field of Genetics and Genomics
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
Healthcare Team's Relationship to the Patient
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
Last modified: January 10, 2018